CN103966338B - 长链非编码rna rmst的应用方法 - Google Patents
长链非编码rna rmst的应用方法 Download PDFInfo
- Publication number
- CN103966338B CN103966338B CN201410225047.8A CN201410225047A CN103966338B CN 103966338 B CN103966338 B CN 103966338B CN 201410225047 A CN201410225047 A CN 201410225047A CN 103966338 B CN103966338 B CN 103966338B
- Authority
- CN
- China
- Prior art keywords
- rmst
- lncrna
- expression
- rna
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108091046869 Telomeric non-coding RNA Proteins 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title abstract description 11
- 229920002477 rna polymer Polymers 0.000 title abstract 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 title abstract 2
- 206010018338 Glioma Diseases 0.000 claims abstract description 41
- 238000004393 prognosis Methods 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 238000003753 real-time PCR Methods 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 108091027963 non-coding RNA Proteins 0.000 claims description 8
- 102000042567 non-coding RNA Human genes 0.000 claims description 8
- 230000003321 amplification Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 abstract description 23
- 238000011160 research Methods 0.000 abstract description 6
- 238000004445 quantitative analysis Methods 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 238000010839 reverse transcription Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 4
- 108020005198 Long Noncoding RNA Proteins 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 3
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091007417 HOX transcript antisense RNA Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 229940048102 triphosphoric acid Drugs 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091033411 PCA3 Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 206010061311 nervous system neoplasm Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种长链非编码RNA(long no‑coding RNA,LncRNA)RMST的应用方法,即用于制备胶质瘤患者的预后制剂,特别是制备出实时荧光定量分析法预测胶质瘤患者预后的试剂盒。通过研究证实LncRNA RMST在胶质瘤组织中表达上调,高表达LncRNA RMST的胶质瘤患者比低表达LncRNA RMST的胶质瘤患者预后差,因此,将Lnc RNA RMST的表达用于胶质瘤患者的预后预测,可以为胶质瘤患者的预后提供强有力的分子生物学依据,具有深远的临床意义和推广性。
Description
技术领域
本发明属于肿瘤分子生物学领域,具体涉及LncRNA RMST在制备胶质瘤患者预后试剂中的应用方法。
背景技术
胶质瘤起源于外胚层,约占神经系统肿瘤的40.49%,是最常见的肿瘤之一,可以在任何年龄的人群中发病,具有很强的增殖能力和血管生成能力,很容易在颅内发生侵袭和转移。虽然其发病率仅占成人肿瘤的2%,但病死率却占所有肿瘤相关死亡的10%。尽管一些治疗方法包括手术治疗、放疗及化疗有很大进展,但是胶质瘤患者特别是恶性胶质瘤的预后仍然很差。目前,对胶质瘤的预后判定没有参考标准,也没有特异性的指标,远远不能适应对人胶质瘤进行预后判定的需求。因此,对人胶质瘤进行预后判定,以便选择最佳治疗方案,显著提高患者生存率,成为神经外科领域亟待解决的重要课题。
lncRNA是一类转录本长度大于200bp的非编码RNA,具有相对较长的核苷酸链,其分子内部具有特定的二级空间结构,能提供与蛋白质结合的多个位点,或与DNA、RNA之间通过碱基互补配对原则发生特异性、动态性相互作用。研究表明,lncRNA可作为人类基因组中一类非常重要的表观遗传调控因子,通过表观遗传、转录调控以及转录后调控等多种机制调控DNA甲基化、组蛋白修饰或染色质重构使基因沉默或激活。近年来,lncRNA作为一类重要的调控分子及其在临床诊断、化疗敏感性和预后评价等方面的应用价值,已经逐渐得到研究者的重视。有研究表明HOTAIR在原发乳腺肿瘤和转移瘤中的表达都会增加,原发肿瘤中HOTAIR的表达水平可以用来有效预测癌转移和死亡。lncRNA PCA3在前列腺癌中高度过表达,这种lncRNA是在尿液中发现的,相当便于临床检测。lncRNA-LALR1通过激活Wnt/β-catenin信号,加速了细胞周期进程,促进了肝细胞增殖。采用药物靶干预lncRNA-LALR1诱导肝脏再生,有可能有益于肝衰竭和肝移植治疗。由此可见,lncRNA作为诊断、预后和治疗的分子标志物具有巨大潜力。
发明内容
本发明的目的是提供一种LncRNA RMST的应用方法,即LncRNA RMST(rhabdomyosarcoma2associated transcript)定位于染色体12q23.1,GeneBank登录号:NR-024037能作为胶质瘤预后的判断标准,用于制备胶质瘤患者的预后制剂,更进一步能够提供一种性价比高,易于推广应用的胶质瘤预后预测试剂盒。
长链非编码RNA RMST的应用方法,所述的长链非编码RNA RMST用于制备胶质瘤患者的预后制剂,该长链非编码RNA RMST的序列见SEQ NO:1。用于制备胶质瘤患者的预后制剂具体包括实时荧光定量PCR检测试剂。
所述的实时荧光定量PCR检测试剂包括进行实时荧光定量PCR的特异性引物:
LncRNA RMST正向引物:5′-AACTCCGTGTCCCTTGTG-3′,
LncRNA RMST反向引物:5′-GGCAGTGGGTGACTGATC-3′。
所述的实时荧光定量PCR检测试剂为试剂盒,
该试剂盒包括:(1)从胶质瘤组织中抽提总RNA所用试剂,包括RNA稳定溶液、Trizol试剂、三氯甲烷、异丙醇、无酶水;(2)以总RNA为模板将LncRNA RMST逆转录为cDNA所用试剂,包括逆转录缓冲液、三磷酸碱基脱氧核苷酸、RNA酶抑制剂、MMLV逆转录酶以及LncRNA RMST所用随机引物;(3)将cDNA实时定量PCR所用试剂,包括LncRNA RMST实时荧光定量PCR特异性引物、U6snRNA内参特异性PCR引物、实时荧光定量SYBR染料、无酶水;
LncRNA RMST实时荧光定量PCR特异性引物:
正向引物5′-AACTCCGTGTCCCTTGTG-3′,
反向引物5′-GGCAGTGGGTGACTGATC-3′,
U6snRNA内参特异性PCR引物:
正向引物为5′-ATTGGAACGATACAGAGAAGATT-3′,
反向引物为5′-GGAACGCTTCACGAATT TG-3′。
在前期研究工作中,申请人通过DIANA-LncBase软件分析与miR-101竞争性结合MRE序列的LncRNA时,发现了LncRNA RMST。申请人在胶质瘤组织中提取RNA,逆转录后进行实时荧光定量PCR分析LncRNA RMST的表达,发现:LncRNA RMST在胶质瘤中表达上调,与正常人脑组织中的表达差异显著。且LncRNA RMST表达水平不同的胶质瘤患者中预后存在明显差异,经Kaplan-Meier生存分析发现LncRNA RMST高表达的胶质瘤患者生存率明显低于低表达的患者;多因素Cox比例风险模型的预后分析发现LncRNA RMST的相对危险度>1,表明LncRNA RMST高表达的患者预后较低表达的患者预后差,所以LncRNARMST的高表达是胶质瘤患者预后风险预测的独立危险因素。据此,申请人提出利用LncRNA RMST制备用于胶质瘤患者预后的制剂。
将LncRNA RMST用于胶质瘤患者预后的检测方法:(1)收集待测个体术后切除的胶质瘤组织,抽提总RNA;(2)以总RNA为模板将RMST逆转录为cDNA;(3)用RMST特异性引物进行实时荧光定量PCR扩增,获得相对表达量2ΔΔCT,当2ΔΔCT>1.87时提示RMST为高表达。
利用本发明的检测制剂可以检测LncRNA RMST在胶质瘤患者中的表达水平,为胶质瘤患者预后预测提供了强有力的分子生物学基础,具有深远的临床意义和推广性。
附图说明
图1为实时荧光定量PCR分析LncRNA RMST在胶质瘤组织与正常脑组织中的表达差异;
图2为LncRNA RMST与37例胶质瘤患者预后的关系。
具体实施方式
以下结合实施例旨在进一步说明本发明,而非限制本发明。
在前期研究工作中,申请人通过DIANA-LncBase软件分析与miR-101竞争性结合MRE序列的LncRNA时,发现了LncRNA RMST。申请人在胶质瘤组织中提取RNA,逆转录后进行实时荧光定量PCR分析LncRNA RMST的表达,发现:LncRNA RMST在胶质瘤组织中表达上调,与正常人脑组织中的表达差异显著(P=0.0282)(图1)。且LncRNA RMST表达水平不同的胶质瘤患者中预后存在明显差异,经Kaplan-Meier生存分析发现LncRNA RMST高表达的胶质瘤患者生存率明显低于低表达的患者(P=0.0035)(图2),多因素Cox比例风险模型的预后分析发现LncRNA RMST的相对危险度>1(RR=1.177),表明LncRNA RMST高表达的患者预后较低表达的患者预后差,LncRNA RMST的高表达是胶质瘤患者预后风险预测的独立危险因素。
实施例1制备LncRNA RMST用于胶质瘤患者预后的试剂盒(50次反应)
1.RNA稳定溶液 50ml
2.异丙醇 100ml
3.三氯甲烷 100ml
4.Trizol 50ml
5.无酶水 10ml
6.1μM随机逆转录引物 50ul
7.5×逆转录缓冲液 200ml
8.10mM三磷酸碱基脱氧核苷酸 100ul
9.40U/μl RNA酶抑制剂 500ul
10.200U/μl MMLV逆转录酶 50ul
11.Premix Ex Taq 50ul
12.10μM Lnc RNA RMST特异性引物 30ul
正向引物5′-AACTCCGTGTCCCTTGTG-3′
反向引物5′-GGCAGTGGGTGACTGATC-3′
13.10μM U6snRNA特异性引物30ul
正向引物为5′-ATTGGAACGATACAGAGAAGATT-3′
反向引物为5′-GGAACGCTTCACGAATTTG-3′。
实施例2胶质瘤组织中Lnc RNA RMST的检测
1、胶质瘤组织的保存:收集待测胶质瘤组织存放于盛有RNA稳定溶液的冻存管中,放至-80℃冰箱备用。
2、组织中RNA的抽提:取适量标本于经180℃烘烤6-8h后的研钵中加入液氮研磨标本,研磨至粉末状后于研钵中加入1ml Trizol研钵标本,研磨成液体状后用移至tube管,加氯仿200μl/mlTrizol于Tube中,用手震荡15-30s,冰上放置5min,4℃12000g离心15min;小心取上层水相入新tube中,加入预冷的异丙醇0.5ml/mlTrizol混匀,-20℃冰箱静置20min,4℃12000g离心10min;弃上清,加入75%DEPC水稀释的乙醇1-2ml混匀,4℃7500g离心5min,尽量弃上清,室温干燥5-10min,加入DEPC水10-20μl溶解RNA。分光光度计测RNA的浓度及质量,OD260/280比值在1.8-2.0之间,-80℃保存。
3、LncRNA RMST逆转录:使用Thermo公司的逆转录试剂盒。20μL逆转录反应的体系如下:
逆转录第一步条件:65℃5分钟
逆转录第二步程序:25℃5分钟,42℃60分钟,70℃5分钟。
4、RMST特异性引物进行实时定量PCR:RMST特异性引物序列由上海生工生物工程有限公司合成。
先将逆转录产物稀释5倍,混匀。20μL反应体系如下:
实时荧光定量PCR反应程序:95℃3分钟,40个循环,95℃10秒,60℃30秒。
LncRNA RMST特异性引物序列为:
F:5'AACTCCGTGTCCCTTGTG3'
R:5'GGCAGTGGGTGACTGATC3'
5、-2ΔΔCT指标的测定:本实验数据采用相对定量的分析方法,U6作为内参基因,数据利用软件GraphPad Prism进行分析。分析发现,与LncRNA RMST在正常脑组织中的表达相比,52例脑胶质瘤患者中LncRNA RMST的表达明显上调,差异有显著性(P=0.0282)。
6、预后判断
通过对实验所采用的52例胶质瘤患者随访统计资料发现,15例患者在随访时由于手机停机或者换号或者其他原因联系不上,最后能联系上的胶质瘤患者或家属为37例,这37例患者或家属接受后续的随访分析。我们详细询问了这些患者或家属首次发病的时间,治疗情况,复发状况及死亡时间等,随访时间为1-46个月。在所选取的胶质瘤患者中,选取荧光定量PCR分析的表达值为参考标准,所得结果降序排列后高于中位数的为LncRNA RMST高表达,共20例,其他为LncRNA RMST低表达,共17例。经Kaplan-Meier生存分析,LncRNARMST高表达患者的生存期较LncRNA RMST低表达的患者短,预后差。差异有统计学意义(P=0.0035)。多因素Cox比例风险模型的预后分析发现LncRNA RMST的相对危险度>1(RR=1.177),表明LncRNA RMST高表达的患者预后较低表达的患者预后差,LncRNA RMST的高表达是胶质瘤患者预后风险预测的独立危险因素。
以上研究表明,LncRNA RMST可作为胶质瘤患者预后的特异性分子标志物。
Claims (1)
1.检测长链非编码RNA RMST表达量的试剂在制备胶质瘤患者的预后制剂中的用途,该长链非编码RNA RMST的序列如SEQ NO:1所示;检测长链非编码RNA RMST表达量的试剂为实时荧光定量PCR检测试剂;所述的实时荧光定量PCR检测试剂包括进行实时荧光定量PCR的特异性引物:
LncRNA RMST正向引物:5′-GGCAGTGGGTGACTGATC-3′,
LncRNA RMST反向引物:5′-AACTCCGTGTCCCTTGTG-3′;
进行实时荧光定量PCR扩增,获得相对表达量2△△CT,当2△△CT>1.87时提示RMST为高表达。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410225047.8A CN103966338B (zh) | 2014-05-26 | 2014-05-26 | 长链非编码rna rmst的应用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410225047.8A CN103966338B (zh) | 2014-05-26 | 2014-05-26 | 长链非编码rna rmst的应用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103966338A CN103966338A (zh) | 2014-08-06 |
CN103966338B true CN103966338B (zh) | 2017-02-15 |
Family
ID=51236340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410225047.8A Expired - Fee Related CN103966338B (zh) | 2014-05-26 | 2014-05-26 | 长链非编码rna rmst的应用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103966338B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107937484A (zh) * | 2017-12-15 | 2018-04-20 | 河南师范大学 | 肝再生相关lncRNA及其筛选方法、抑制剂和应用 |
CN108192974B (zh) * | 2018-03-02 | 2021-11-05 | 中南大学湘雅医院 | 长链非编码rna linc00842作为生物标志物在制备肺腺癌预后检测制剂中的应用 |
CN108192976B (zh) * | 2018-03-02 | 2021-06-04 | 中南大学湘雅医院 | 长链非编码rna linc00336作为生物标志物在制备肺鳞癌预后检测制剂中的应用 |
CN108192975B (zh) * | 2018-03-02 | 2021-06-04 | 中南大学湘雅医院 | 长链非编码rna linc00559作为生物标志物在制备肺鳞癌预后检测制剂中的应用 |
CN108179193B (zh) * | 2018-03-02 | 2021-11-05 | 中南大学湘雅医院 | Mettl14基因作为生物标志物在制备肺腺癌预后检测制剂中的应用 |
CN108504737B (zh) * | 2018-04-11 | 2021-09-07 | 中南大学湘雅医院 | 一种长链非编码rna tralr的应用 |
CN109609645B (zh) * | 2019-01-22 | 2022-06-21 | 中南大学湘雅医院 | 检测IncRNA LNC_004208表达量的试剂在制备胶质瘤诊断试剂中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013138427A1 (en) * | 2012-03-16 | 2013-09-19 | The General Hospital Corporation | Microvesicle-mediated delivery of therapeutic molecules |
-
2014
- 2014-05-26 CN CN201410225047.8A patent/CN103966338B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013138427A1 (en) * | 2012-03-16 | 2013-09-19 | The General Hospital Corporation | Microvesicle-mediated delivery of therapeutic molecules |
Non-Patent Citations (3)
Title |
---|
Homo sapiens rhabdomyosarcoma 2 associated transcript (non-protein coding) (RMST), long non-coding RNA;Chan A. S.;《Genbank》;20080725;序列表 * |
Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling;Guido Reifenberger;《International Journal of Cancer》;20140311;第00卷;第25页表3 * |
Zhou Du.Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer.《Nature structural & molecular biology》.2013,全文. * |
Also Published As
Publication number | Publication date |
---|---|
CN103966338A (zh) | 2014-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103966338B (zh) | 长链非编码rna rmst的应用方法 | |
Masuda et al. | Clinical and biological significance of circulating tumor cells in cancer | |
Yang et al. | The role of microRNA in human lung squamous cell carcinoma | |
Wang et al. | Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy | |
Tan et al. | Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients | |
CN101824464A (zh) | miRNA表达谱在预测肺癌病人对放射治疗敏感性方面的应用 | |
Wang et al. | Expression of lncRNA HULC in cervical cancer and its correlation with tumor progression and patient survival. | |
CN108192976B (zh) | 长链非编码rna linc00336作为生物标志物在制备肺鳞癌预后检测制剂中的应用 | |
CN108456731A (zh) | 长链非编码rna linc00336作为生物标志物在制备肺腺癌预后检测制剂中的应用 | |
CN108192974B (zh) | 长链非编码rna linc00842作为生物标志物在制备肺腺癌预后检测制剂中的应用 | |
CN103966339B (zh) | 长链非编码rna crnde的应用方法 | |
CN108179193A (zh) | Mettl14基因作为生物标志物在制备肺腺癌预后检测制剂中的应用 | |
CN109576366B (zh) | lnc-TALC作为分子标志物在评估胶质母细胞瘤TMZ化疗疗效和预后中的用途 | |
CN103981269B (zh) | 长链非编码rna crym-as1的应用方法 | |
Mazzaferro et al. | Alpha‐fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better | |
CN107586848A (zh) | 胶质瘤预后标志物circ8:127890589|127890998及应用 | |
CN107586844A (zh) | 胶质瘤预后标志物Circ9:135881633|135883078的应用 | |
CN108192975A (zh) | 长链非编码rna linc00559作为生物标志物在制备肺鳞癌预后检测制剂中的应用 | |
CN102424843B (zh) | 人miR-183/96/182簇的应用及其检测试剂盒 | |
CN107937529A (zh) | 胶质瘤诊断标志物hsa_circ_0135404及应用 | |
CN107937539A (zh) | 胶质瘤预后标志物hsa_circ_0135404及应用 | |
CN104975096B (zh) | 非小细胞肺癌的一种诊断标志物 | |
CN108192973B (zh) | 长链非编码rna linc00559作为生物标志物在制备肺腺癌预后检测制剂中的应用 | |
CN107937541B (zh) | 胶质瘤预后标志物circ1:1804419|1806538及应用 | |
CN110734976B (zh) | 长链非编码rna linc00263在制备肺腺癌预后检测制剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170215 |